1 **Istradefylline, an adenosine A2a receptor antagonist, ameliorates neutrophilic airway**
 2 **inflammation and psoriasis in mice.**

3

4 **Running title: Adenosine A2a receptor antagonist ameliorates neutrophilic**
 5 **inflammation**

6

7 Mieko Tokano ^{a,b}, Masaaki Kawano^a, Rie Takagi^a, and Sho Matsushita^{a, c*}

8 ^a Departments of Allergy and Immunology, Faculty of Medicine, Saitama Medical University,
 9 38 Morohongo, Moroyama, Saitama 350-0495, Japan

10 ^b Department of Neurology, Saitama Medical University, 38 Morohongo, Moroyama,
 11 Saitama, 350-0495, Japan

12 ^c Allergy Center, Saitama Medical University, 38 Morohongo, Moroyama, Saitama 350-0495,
 13 Japan

14

15 *Correspondence: Sho Matsushita, M.D., Ph.D.

16 Department of Allergy and Immunology, Faculty of Medicine, Saitama Medical University,
 17 38 Morohongo, Moroyama, Saitama 350-0495, Japan

18 Tel: +81-49-276-1172; Fax: +81-49-294-2274; E-mail: shomat@saitama-med.ac.jp

19

20

21

22 **Abstract**

23 **Objective:** Extracellular adenosine is produced from secreted ATP by cluster of differentiation
 24 (CD)39 and CD73. Both are critical nucleotide metabolizing enzymes of the adenosine
 25 generating pathway and are secreted by neuronal or immune cells. Adenosine plays a role in
 26 energy processes, neurotransmission, and endogenous regulation of inflammatory responses.
 27 Istradefylline is a selective adenosine A2a receptor (A2aR) antagonist used for the treatment
 28 of Parkinson's disease. We have reported that adenosine primes hypersecretion of interleukin
 29 (IL)-17A via A2aR. Istradefylline, as well as an inhibitor of CD39 (ARL67156) and an
 30 inhibitor of CD73 (AMP-CP), suppressed IL-17A production, and the administration of
 31 istradefylline to mice with experimental autoimmune encephalomyelitis (EAE) led to the
 32 marked amelioration of the disease. These previous results suggest that adenosine is an
 33 endogenous modulator of neutrophilic inflammation. We investigated the effect of
 34 istradefylline, ARL67156 and AMP-CP on other mouse models of neutrophilic inflammation.
 35 **Methods:** We tested the effect of istradefylline, ARL67156 and AMP-CP on OVA-induced
 36 neutrophilic airway inflammation or imiquimod (IMQ)-induced psoriasis in mice. These two
 37 model mice received these drugs orally or percutaneously, respectively. The production of
 38 IL-17A in the lung and ear thickness were used as an index of the effects.
 39 **Results:** We show that istradefylline, ARL67156 and AMP-CP suppressed the OVA-induced
 40 IL-17A production in the lung and imiquimod-induced psoriasis.
 41 **Conclusion:** These results indicate that adenosine-mediated IL-17A production plays a role
 42 in neutrophilic inflammation models, and moreover, istradefylline, ARL67156, and AMP-CP
 43 are effective in animal models of neutrophilic inflammation. Some clinical relevancies in
 44 COVID-19 are discussed. (248 words)

45
 46 **Keywords:** Adenosine A2a receptor, Neutrophilic inflammatory response, Psoriasis, Severe

47 acute respiratory syndrome coronavirus 2, Th17 cells

48

49 **Introduction**

50 Adenosine, a molecular moiety of ATP, ADP, and AMP, is involved in energy
51 processes and is essential for the phenomena of life. Extracellular adenosine is produced from
52 secreted ATP by ectonucleotidases, such as the E-NTPDase cluster of differentiation (CD)39,
53 which converts ATP or ADP to ADP or AMP, respectively, and the 5'-nucleotidase CD73,
54 which dephosphorylates AMP to adenosine. CD39 and CD73 are expressed on the surface of
55 endothelial cells^{1,2)} and immune cells³⁻⁵⁾. Adenosine binds to adenosine receptors expressed
56 on the cell surface. There are four subtypes of adenosine receptors, A1, A2a, A2b, and A3,
57 which belong to a superfamily of membrane proteins called the G protein-coupled receptor
58 family. A2aR and A2bR signal the Gs protein to trigger cAMP synthesis. On the other hand,
59 A1R and A3R signal the Gi protein to trigger cAMP degradation⁶⁾. A1R, A2bR and A3R are
60 widely expressed in the body. In contrast, A2aR is expressed at high levels in only a few
61 regions of the body, namely the striatum, olfactory tubercle, nucleus accumbens, endothelial
62 cells, vascular smooth muscle cells, platelets, and immune cells⁷⁾. A1R and A2aR are
63 high-affinity receptors, whereas A2bR and A3R are low-affinity receptors^{8,9)}.

64 The purine nucleoside adenosine also plays a role as a neurotransmitter, primarily
65 in the striatum, olfactory tubercle and nucleus accumbens¹⁰⁾. Istradefylline is a selective
66 A2aR antagonist used for the treatment of Parkinson's disease¹¹⁾. Furthermore, adenosine is a
67 potent endogenous regulator of inflammation and immune reactions⁶⁾. However, the
68 molecular mechanisms underlying its effects are largely unknown. In previous a study,
69 adenosine was reported to induce T-helper (Th)17 differentiation by activating A2bR¹²⁾.

70 Th17 cells are a subset of T-helper cells that differentiate from naïve CD4⁺ T cells
71 in the presence of tumor growth factor (TGF)- β and interleukin (IL)-6. These cytokines are
72 secreted by antigen-presenting cells in response to stimulation via T cell receptor (TCR)
73 antigen¹³⁻¹⁵⁾. IL-17A production by Th17 cells drives neutrophil recruitment and neutrophilic

inflammation^{16,17}). The IL-17A-mediated responses are induced in receptor-expressing cells, such as endothelial cells, epithelial cells, and fibroblasts¹⁸). Neutrophilic inflammation is associated with many diseases¹⁹), including autoimmune diseases²⁰⁻²³), neutrophilic airway inflammation^{24,25}), psoriasis^{26,27}), severe atopic dermatitis²⁸), and multiple sclerosis²⁹⁻³⁴). There are currently no specific therapies that use low-molecular weight chemicals for neutrophilic inflammation, nevertheless corticosteroids are a specific therapy for eosinophilic inflammation. However, recent studies by ourselves and others suggested that dopamine D1-like receptor antagonists and dopamine D2-like receptor agonists suppress neutrophilic inflammation by suppressing Th17 differentiation and activation³⁵⁻³⁷). We recently reported that adenosine is also produced by activated CD4⁺ T cells, mainly during T cell-APC interactions, primes the hypersecretion of IL-17A by CD4⁺ T cells, where A2aR plays a role in the hypersecretion of IL-17A. Istradefylline, an inhibitor of CD39 (ARL67156), and an inhibitor of CD73 (AMP-CP) suppressed IL-17A production, and the administration of istradefylline to mice with experimental autoimmune encephalomyelitis led to the marked amelioration of symptoms³⁸). These results suggest that adenosine is an endogenous modulator of neutrophilic inflammation.

In this study, we tested the effect of istradefylline, ARL67156, and AMP-CP on other models of neutrophilic inflammation, such as OVA-induced neutrophilic airway inflammation and imiquimod-induced psoriasis. We show that istradefylline, ARL67156 and AMP-CP are effective in animal models of neutrophilic inflammation.

94

95

96 **Materials and methods**

97 *Mice*

98 OVA TCR-transgenic DO11.10 mice were obtained from The Jackson Laboratory
99 (Bar Harbor, ME). C57BL/6 mice were obtained from Japan SLC (Shizuoka, Japan). Mice
100 were housed in appropriate animal care facilities at Saitama Medical University and handled
101 according to the international guidelines for experiments with animals. All experiments were
102 approved by the Animal Research Committee of Saitama Medical University.

103

104 *Measurement of cytokine concentrations in the lung*

105 Airway inflammation was induced as described previously³⁶. Briefly,
106 eight-week-old female DO11.10 mice received a subcutaneous inguinal injection (100
107 µg/mouse) of 2 mg/mL OVA (Sigma) in PBS (-) emulsified in complete Freund's adjuvant
108 (CFA) containing mycobacterium tuberculosis H37Ra (100 µg/mouse; Difco) on day -8.
109 Mice also received oral PBS (-), an A2aR antagonist (Istradefylline) (6 µg/mouse), an
110 inhibitor of CD39 (ARL67156, Tocris) (0.5 mg/mouse) or an inhibitor of CD73 inhibitor
111 (adenosine 5'-(α, β-methylene) diphosphate (AMP-CP; Tocris) (0.5 mg/mouse) on days -10,
112 -8, -6, -4, -2, and -1. Mice were challenged with an aerosolized solution of 3% OVA or PBS
113 (-) for 10 min on day -1. The mice were analyzed on day 0. Lung cells were prepared as
114 previously described³⁶. Briefly, the left lungs were cut out, homogenized, and incubated in
115 10 mL of DMEM medium containing 10% FCS, 100 U/mL penicillin, 100 µg/mL
116 streptomycin, 1 mM sodium pyruvate, 50 µM 2-mercaptoethanol, 50 µg/mL gentamycin, 1
117 µg/mL amphotericin, and collagenase from clostridium histolyticum (Sigma-Aldrich) for one
118 hour. Following incubation, the lung lymphocytes were washed twice. Lung lymphocytes (1
119 × 10⁶) were seeded in a round-bottomed 96-well plate and then incubated in in 500 µL of
120 DMEM medium containing 10% FCS, 100 U/mL penicillin, 100 µg/mL streptomycin, 1 mM

sodium pyruvate, 50 μ M 2-mercaptoethanol, 50 μ g/mL gentamycin, and 1 μ g/mL amphotericin for four days. The supernatant was then collected for the IL-17A, IFN- γ , and IL-5 ELISAs.

Histological examination

The histological examination was performed as previously reported³⁶. The right lungs were resected, fixed with 10% neutralized buffered formalin (Wako), and embedded in paraffin. Three-micrometer-thick sections were stained with hematoxylin and eosin.

The mouse model of imiquimod (IMQ)-induced psoriasis

Psoriasis was induced in the mouse model as previously described³⁹. Briefly, C57BL/6 mice were treated with either IMQ cream containing 5% IMQ (Mochida Pharmaceutical) or sham cream, which was applied on the ears for 5 consecutive days. On day 9, the ear thickness (μ m) was measured. In the treatment groups, a cream containing 5% A2aR antagonist (Istradefylline), liquid containing 10 mM CD39 inhibitor (ARL67156), or liquid containing 10 mM CD73 inhibitor (AMP-CP) was used.

Cytokine ELISAs

The concentrations of IFN- γ , IL-5, and IL-17A in cell supernatants were measured using specific ELISA kits (DuoSet Kit, R&D). Any value below the lower limit of detection (15.6 pg/mL) was set to 0. No cytokine cross-reactivity was observed within the detection ranges of the kits. If necessary, samples were diluted appropriately so that the measurements fell within the appropriate detection range for each cytokine.

Statistical analysis

Differences between two groups were analyzed using an unpaired Student's *t*-test. Differences between three or more groups were analyzed using a one-way ANOVA with Tukey's post-hoc test. Clinical scores were analyzed using a non-parametric Mann-Whitney U-test. All calculations were performed using KaleidaGraph software program (Synergy software, Reading, PA, USA). P values of <0.05 were considered to indicate statistical significance.

Results

An adenosine A2a receptor antagonist, istradefylline, suppresses OVA-induced neutrophilic airway inflammation in DO11.10 mice

First, we tested the effect of an adenosine A2a receptor antagonist, istradefylline, on OVA-induced neutrophilic airway inflammation in OVA TCR-transgenic DO11.10 mice. DO11.10 mice were challenged with nebulized OVA or with PBS as a control. The administration of istradefylline was performed starting from 10 days before nebulization (Fig.1A). Our previous study showed a clear correlation between IL-17A in the lung and neutrophilic airway inflammation³⁶. Indeed, the concentration of IL-17A increased in the lungs of OVA-challenged DO11.10 mice, which were suppressed by istradefylline (Fig.1B). Time course studies showed that the production of IL-17A was time-dependent (Fig.1C). We observed that istradefylline treatment suppressed IL-17A (a Th17-related cytokine) and IFN- γ (a Th1-related cytokine) secretion on day 4 and had no significant effect on IL-5 (a Th2-related cytokine) secretion (Fig.1D).

Istradefylline suppresses OVA-induced neutrophil infiltration in DO11.10 mice

The histology of OVA-challenged DO11.10 mice showed prominent neutrophil infiltration into the peribronchial area (Fig. 2A), while the infiltration declined in mice that

received istradefylline (Fig. 2B). Accordingly, istradefyllin-treatment suppressed neutrophilic airway inflammation.

ARL67156 and AMP-CP also suppress OVA-induced neutrophilic airway inflammation in DO11.10 mice

Since we found that istradefylline suppressed the production of IL-17A in the lung, we next examined the effect of a CD39 inhibitor (ARL67156) and a CD73 inhibitor (AMP-CP) on OVA-induced neutrophilic airway inflammation. ARL67156 and AMP-CP inhibit the production of adenosine (data not shown). DO11.10 mice were challenged with nebulized OVA, and the administration of ARL67156 and AMP-CP was performed from 10 days before OVA nebulization. As in the case of istradefylline treatment, ARL67156 and AMP-CP treatment suppressed the production of IL-17A in the lung (Fig.3A, B). This suggests that adenosine promotes neutrophilic airway inflammation by hypersecretion of IL-17A.

Istradefylline, ARL67156, and AMP-CP suppress imiquimod (IMQ)-induced psoriasis in mice

Psoriasis is a Th17-mediated disease^{26,27}. Indeed, the skin infiltration of neutrophils, activated monocytes, Th17 cells are observed in psoriasis and a mouse model of IMQ-induced psoriasis⁴⁰⁻⁴². Mice were treated with either 5% IMQ cream or sham cream. In the treatment groups, 5% istradefylline-containing cream, 10 mM ARL67156 or 10 mM AMP-CP-containing liquid was used. Istradefylline, ARL67156, and AMP-CP significantly suppressed the effect of IMQ (Fig. 4A, B, C). All these observations collectively suggest that the oral or transdermal administration of istradefylline, ARL67156, and AMP-CP suppresses Th17-mediated disease.

Discussion

Atopic asthma is usually triggered by allergens or by antigen-non-specific stimuli, in which Th2 inflammation, group 2 innate lymphoid cell (ILC2) activation and eosinophilic inflammation play a pivotal role. Approximately 50% of elderly and 90% of young individuals with asthma show the atopic phenotype. On the other hand, the recruitment and activation of neutrophils in airways are associated with resistance to corticosteroids. Approximately 40% of elderly patients with asthma have neutrophilic airway inflammation^{24,25,43,44}, accompanying increased bronchial IL-17⁺ cells⁴⁵⁻⁴⁷. The TCR-transgenic DO11.10 mice have TCR, which specifically recognizes MHC class II-OVA peptide complex. OVA nebulization alone could induce IL-17-dependent neutrophilic airway inflammation^{28,36,48-50}. This response is OVA-specific, as other antigens could not induce neutrophilic airway inflammation. In addition, deletion of the IL-17 gene suppressed the neutrophilic airway inflammation⁵⁰. Thus, this animal model is similar to the pathogenesis of antigen-induced Th17-mediated neutrophilic airway inflammation³⁶. Our studies demonstrate that istradefyllin-treatment suppressed IL-17-dependent neutrophilic airway inflammation in DO11.10 mice. Similarly, ARL67156 and AMP-CP, which inhibit the production of adenosine, suppressed IL-17-dependent neutrophilic airway inflammation, which corroborates our previous findings³⁸. Furthermore, the modulation of signaling via A2aR might ameliorate autoimmune diseases, including allergy and infections. The latter may include disseminated intravascular coagulation (DIC) or acute respiratory distress syndrome (ARDS) in SARS-CoV-2 disease (COVID-19), which is reportedly associated with neutrophil extracellular traps (NETs)⁵¹⁻⁵⁴. In recent previous studies, patients with severe COVID-19 showed the aberrant activation of neutrophils and Th17 promotion⁵⁵, and IL-17 can serve as a biomarker of the severity of COVID-19⁵⁶. Indeed, autopsy samples from the lungs of COVID-19 patients showed neutrophil infiltration in pulmonary capillaries⁵⁷, and

the peripheral blood of patients showed an increased frequency of Th17 cells⁵⁸). Accordingly, it is conceivable that istradefyllin-treatment may suppress IL-17 secretion and neutrophilic airway inflammation in COVID-19.

Psoriasis had long been characterized as a Th1-mediated disease because psoriatic lesions showed the elevated mRNA expression of Th1 cytokines (IFN- γ and TNF- α)⁵⁹). Recent studies have shown that the pathology of psoriasis is strongly dependent on IL-17A⁶⁰). In an IMQ-induced mouse model, activated Th17 cells and marked skin infiltration of neutrophils are observed^{40,42}). Our studies demonstrate that istradefylline, ARL67156, and AMP-CP suppress IMQ-induced murine psoriasis. It is therefore conceivable that adenosine promotes IL-17A production in an IMQ -induced mouse model. We also confirmed that $\gamma\delta$ T cells secreted IL-17A after stimulation with agonistic anti-CD3/CD28 antibodies in the presence of adenosine (data not shown). In the dermis with psoriasis, IL-23 from keratinocytes, activated Langerhans cells, macrophages, and dendritic cells are capable of promoting the production of IL-17A by $\gamma\delta$ T cells⁶¹⁻⁶³). Adenosine-mediated IL-17A production may play an important role in psoriasis.

Our study demonstrated that istradefyllin as well as ARL67156 and AMP-CP suppress neutrophilic airway inflammation and psoriasis in mice, which strongly attests to the *in vivo* relevance of adenosine-mediated IL-17A production. It is also suggested that istradefylline as well as ARL67156 and AMP-CP may be effective treatments for Th17-mediated diseases, such as psoriasis, neutrophilic bronchial asthma, and autoimmune diseases, due to their suppression of the hypersecretion of IL-17A from Th17 cells. Some researchers argue that an A2aR agonist, CGS21680, suppresses Th17 differentiation⁶⁴⁻⁶⁶). Because CGS21680 is much less selective than the A2aR agonist we used in a recent previous study (PSB0777)³⁸), it is highly conceivable that these studies gave contradictory results.

It is suggested that the concentrations of adenosine are increased as much as 50 times by physiological stimuli such as hypoxia, hypoglycemia, and ischemia⁶⁷). A previous study also suggested that extracellular adenosine is transported into the cell by transporters or that it is rapidly broken down by adenosine deaminase or adenosine kinase⁶⁸). It is probable that adenosine induces neutrophilic inflammation in acute stages (*i.e.*, in the innate immunity-acquired immunity interface).

Conflict of Interest

Sho Matsushita is an employee of iMmno, Inc.

The other authors declare no conflicts of interest in association with the present study.

Acknowledgments

This work was supported by a Grant-in-Aid for Scientific Research (C) (no. 19K07201), awarded to M.K., a Grant-in-Aid for Young Scientists (B) (no. 18K15327) to R.T., and a Grant-in-Aid for Scientific Research (C) (no. 19K08887) awarded to S.M. by the Japanese Society for the Promotion of Science. This work was also supported by the 44th and 45th Science Research Promotion Fund, awarded to M.K. by the Promotion and Mutual Aid Corporation for Private Schools of Japan.

Abbreviations

Th, T-helper; CD, cluster of differentiation; TGF, tumor growth factor; IL, interleukin; APCs, antigen presenting cells; EAE, experimental autoimmune encephalomyelitis; CFA, complete Freund's adjuvant; OVA, ovalbumin; IMQ, imiquimod; Ab, antibody; n, number of repeat experiments; SD, standard deviation.

Author contributions

M.T., R.T., M.K., and S.M., performed the experiments. M.T., M.K., and S.M., conceived and designed the experiments. M.T., M.K., and S.M., wrote the manuscript. All authors discussed the results and commented on the manuscript.

References

- 1) Kaczmarek, E., K. Koziak, J. Sevigny, J. B. Siegel, J. Anrather, A. R. Beaudoin, F. H. Bach, and S. C. Robson. 1996. Identification and characterization of CD39/vascular ATP diphosphohydrolase. *J Biol Chem* 271: 33116-33122.
- 2) Jalkanen, S., and M. Salmi. 2008. VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. *Arteriosclerosis, thrombosis, and vascular biology* 28: 18-26.
- 3) Junger, W. G. 2011. Immune cell regulation by autocrine purinergic signalling. *Nat Rev Immunol* 11: 201-212.
- 4) Whiteside, T. L., M. Mandapathil, and P. Schuler. 2011. The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). *Curr Med Chem* 18: 5217-5223.
- 5) Allard, B., M. S. Longhi, S. C. Robson, and J. Stagg. 2017. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. *Immunol Rev* 276: 121-144.
- 6) Cronstein, B. N., and M. Sitkovsky. 2017. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. *Nat Rev Rheumatol* 13:41-51.
- 7) Ciruela, F., C. Albergaria, A. Soriano, L. Cuffí, L. Carbonell, S. Sánchez, J. Gandía, and V. Fernández-Dueñas. 2010. Adenosine receptors interacting proteins (ARIPs): Behind the biology of adenosine signaling. *Biochim Biophys Acta* 1798:9-20.
- 8) Fredholm, B.B., G. Arslan, L. Halldner, B. Kull, G. Schulte, and W. Wasserman. 2000. Structure and function of adenosine receptors and their genes.

- 297 *Naunyn-Schmiedeberg's Arch. Pharmacol* 362, 364-374.
- 298 9) Livingston, M., L.G.Heaney, and M.Ennis. 2004. Adenosine, inflammation and asthma--a
299 review. *Inflamm Res* 53:171-178.
- 300 10) Mori, A., and T. Shindou. 2003. Modulation of GABAergic transmission in the
301 striatopallidal system by adenosine A2A receptors: a potential mechanism for the
302 antiparkinsonian effects of A2A antagonists. 2003. *Neurology* 61 (11 Suppl 6):S44-48.
- 303 11) Takahashi, M., M. Fujita, N. Asai, M. Saki, and A. Mori. 2018. Safety and effectiveness
304 of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing
305 surveillance study in Japan. *Expert Opin Pharmacother* 19:1635-1642.
- 306 12) Wilson, J. M., C. C. Kurtz, S. G. Black, W. G. Ross, M. S. Alam, J. Linden, and P. B.
307 Ernst. 2011. The A2B adenosine receptor promotes Th17 differentiation via stimulation of
308 dendritic cell IL-6. *J Immunol* 186: 6746-6752.
- 309 13) Matsuzaki, G., and M. Umemura. 2007. Interleukin-17 as an effector molecule of innate
310 and acquired immunity against infections. *Microbiol Immunol* 51: 1139-1147.
- 311 14) Manel, N., D. Unutmaz, and D. R. Littman. 2008. The differentiation of human T(H)-17
312 cells requires transforming growth factor-beta and induction of the nuclear receptor
313 RORgamma. *Nat Immunol* 9: 641-649.
- 314 15) Ivanov, II, L. Zhou, and D. R. Littman. 2007. Transcriptional regulation of Th17 cell
315 differentiation. *Semin Immunol* 19: 409-417.
- 316 16) Aggarwal, S., and A.L. Gurney. 2002. IL-17: prototype member of an emerging cytokine
317 family. *J Leukoc Biol* 71:1-8.
- 318 17) Kolls J.K., and A. Linden. 2004. Interleukin-17 family members and inflammation.
319 *Immunity* 21: 467-476.
- 320 18) Ouyang, W., J.K. Kolls, and Y Zheng. 2008. The biological functions of T helper 17 cell
321 effector cytokines in inflammation. *Immunity* 28:454-467.

- 19) Tesmer, L. A., S. K. Lundy, S. Sarkar, and D. A. Fox. 2008. Th17 cells in human disease. *Immunol Rev* 223: 87-113.
- 20) Ogura, H., M. Murakami, Y. Okuyama, M. Tsuruoka, C. Kitabayashi, M. Kanamoto, M. Nishihara, Y. Iwakura, and T. Hirano. 2008. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. *Immunity* 29, 628-636.
- 21) Leng, R.X., G.M. Chen, H.F. Pan, and D.Q. Ye. 2010. The role of IL-23/IL-17 axis in the etiopathogenesis of Behçet's disease. *Clin Rheumatol* 29, 1209.
- 22) Arayssi, T., and A. Hamdan. 2004. New insights into the pathogenesis and therapy of Behçet's disease. *Curr Opin Pharmacol* 4:183-188.
- 23) Hirota, K., M. Hashimoto, H. Yoshitomi, S. Tanaka, T. Nomura, T. Yamaguchi, Y. Iwakura, N. Sakaguchi, and S. Sakaguchi. 2007. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. *J Exp Med* 204, 41-47.
- 24) McKinley L., J. F. Alcorn, A. Peterson, R. B. Dupont, S. Kapadia, A. Logar, A. Henry, C. G. Irvin, J. D. Piganelli, A. Ray, J. K. Kolls. 2008. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. *J. Immunol.* 181: 4089-4097.
- 25) Lindén A. 2001. Role of interleukin-17 and the neutrophil in asthma. *Int. Arch. Allergy Immunol.* 126: 179-184.
- 26) Rizzo, H.L., S. Kagami, K.G. Phillips, S.E. Kurtz, S.L. Jacques, and A. Blauvelt. 2011. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. *J Immunol* 186, 1495-1502.
- 27) Cai, Y., X. Shen, C. Ding, C. Qi, K. Li, X. Li, V. R. Jala, H. Zhang, T. Wang, J. Zheng, and J. Yan. 2011. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. *Immunity* 35, 596-610.

- 28) Nakae, S. Y. Komiyama, A. Nambu, K. Sudo, M. Iwase, I. Homma, K. Sekikawa, M. Asano, and Y. Iwakura. 2002. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. *Immunity* 17, 375-387.
- 29) Komiyama, Y. S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo, Y. Iwakura. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. *J Immunol* 177: 566-73.
- 30) Matusevicius, D., P Kivisäkk, B He, N Kostulas, V Ozenci, S Fredrikson, and H Link. 1999. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. *Mult Scler* 5: 101-4.
- 31) Jadidi-Niaragh, F., and A Mirshafiey. 2011. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. *Scand J Immunol* 74: 1-13.
- 32) Lock, C., G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, P. Klonowski, A. Austin, N. Lad, N. Kaminski, S. J. Galli, J. R. Oksenberg, C. S. Raine, R. Heller, and L. Steinman. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. *Nat Med* 8: 500-508.
- 33) Vaknin-Dembinsky, A., K. Balashov, and H. L. Weiner. 2006. IL-23 is increased in dendritic cells in multiple sclerosis and downregulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. *J. Immunol.* 176: 7768-7774.
- 34) Pierson, E. R., C. A. Wagner, and J. M. Goverman. 2018. The contribution of neutrophils to CNS autoimmunity. *Clin Immunol.* 2018; 189: 23-28.
- 35) Nakano, K., K. Yamaoka, K. Hanami, K. Saito, Y. Sasaguri, N. Yanagihara, S. Tanaka, I. Katsuki, S. Matsushita, and Y. Tanaka. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T Cells and D1-like receptor antagonist

SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. *J. Immunol* 186: 3745-3752.

36) Nakagome, K., M. Imamura, H. Okada, K. Kawahata, T. Inoue, K. Hashimoto, H. Harada, T. Higashi, R. Takagi, K. Nakano, K. Hagiwara, M. Kanazawa, M. Dohi, M. Nagata, and S. Matsushita. 2011. Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and OVA-Ag-induced neutrophilic airway inflammation. *J. Immunol* 186: 5975-5982.

37) Arreola, R., Alvarez-Herrera, S., Perez-Sanchez, G., Becerril-Villanueva, E., Cruz-Fuentes, C., Flores-Gutierrez, E.O., Garces-Alvarez, M. E., de la Cruz-Aguilera, D.L., Medina-Rivero, E., Hurtado-Alvarado, G., Quintero-Fabian, S., Pavon, L. 2016. Immunomodulatory Effects Mediated by Dopamine. *J. Immunol. Res* 2016:3160486.

38) Tokano, M., S. Matsushita, R. Takagi, T. Yamamoto, and M. Kawano. 2021. Extracellular adenosine induces hypersecretion of IL-17A by T-helper 17 cells through the adenosine A2a receptor to promote neutrophilic inflammation. *bioRxiv* 441713; doi: <https://doi.org/10.1101/2021.04.29.441713>

39) Takagi, R., M. Kawano, T. Sato, and S. Matsushita. 2021. Tannic acid, a dopamine receptor agonist, ameliorates periodontitis, atopic dermatitis and psoriasis in animal models. *Current Trends Immunol* 22:11-17.

40) Malki, K. E., S.H. Karbach, J. Huppert, M. Zayoud, S. Reissig, R. Schüler, A. Nikolaev, K. Karram, T. Münzel, C. R. W. Kuhlmann, H. J. Luhmann, E. V. Stebut, S. Wörtge, F. C. Kurschus, and A. Waisman. 2013. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor signaling. *J Invest Dermatol* 133:441-451.

41) Fitts, L.F., S. Mourits, J. S. A. Voerman, M. Kant, L. Boon, J. D. Laman, F. Cornelissen, A. Mus, E. Florencio, E. P. Prens, and E. Lubberts. 2009. Imiquimod-induced psoriasis-like

397 skin inflammation in mice is mediated via the IL-23/IL-17 axis. *J Immunol*
398 182:5836-5845.

399 42) Moos, S., A. N. Mohebiany, A. Waisman, and F. C. Kurschus. 2019. Imiquimod-induced
400 psoriasis in mice depends on the IL-17 signaling of keratinocytes. *J Invest Dermatol*
401 139:1110-1117.

402 43) Douwes, J., P. Gibson, J. Pekkanen, and N. 2002. Pearce. Non-eosinophilic asthma:
403 importance and possible mechanisms. *Thorax* 57: 643-648.

404 44) Holgate, S. T., and R. Polosa. 2006. The mechanisms, diagnosis, and management of
405 severe asthma in adults. *Lancet* 368: 780-793.

406 45) Barczyk, A., W Pierzchala, and E Sozańska. 2003. Interleukin-17 in sputum correlates
407 with airway hyperresponsiveness to methacholine. *Respir. Med* 97: 726-733.

408 46) Al-Ramli W., D. Préfontaine, F. Chouiali, J. G. Martin, R. Olivenstein, C. Lemièrre, and Q.
409 Hamid. 2009. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. *J.*
410 *Allergy Clin. Immunol* 123: 1185-1187.

411 47) Bullone, M., V. Carriero, F. Bertolini, A. Folino, A. Mannelli, A. D. Stefano, I. Gnemmi,
412 R. Torchio, and F. L. M. Ricciardolo. 2019. Elevated serum IgE, oral corticosteroid
413 dependence and IL-17/22 expression in highly neutrophilic asthma. *Eur Respir J* 54:
414 1900068.

415 48) Knott, P. G., P R Gater, and C P Bertrand. 2000. Airway inflammation driven by
416 antigen-specific resident lung CD4(+) T cells in alphabeta-T cell receptor transgenic mice.
417 *Am J Respir Crit Care Med* 161: 1340-1348

418 49) Wilder, J. A., D. D. Collie, D. E. Bice, Y. Tesfaigzi, C. R. Lyons, and M. F. Lipscomb.
419 2001. Ovalbumin aerosols induce airway hyperreactivity in naïve DO11.10 T cell
420 receptor transgenic mice without pulmonary eosinophilia or OVA-specific antibody. *J*
421 *Leukoc Biol* 69: 538-47.

- 50) Nakae, S., H. Suto, G. J. Berry, S.J. Galli. 2007. Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. *Blood* 109: 3640-8.
- 51) Middleton, E. A., X. He, F. Denorme, R. A. Campbell, D. Ng, S. P. Salvatore, M. Mostyka, A. Baxter-Stoltzfus, A. C. Borczuk, M. Loda , M. J. Cody, B. K. Manne, I. Portier, E. S. Harris, A. C. Petrey, E. J. Beswick, A.F. Caulin, A. Iovino, L. M. Abegglen , A.S. Weyrich, M. T. Rondina, M. Egeblad, J. D. Schiffman, and C. C. Yost. 2020. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. *Blood* 136:1169-1179
- 52) Parackova, Z., I. Zentsova, M. Bloomfield, P. Vrabцова, J. Smetanova, A. Klocperk, G. Mesežnikov, L. F. C. Mendez, T. Vymazal, and A. Sediva. 2020. Disharmonic inflammatory signatures in COVID-19: Augmented neutrophils' but impaired monocytes' and dendritic cells' responsiveness. *Cells* 9:2206.
- 53) Tomar, B., H. Anders, J. Desai, and S. R. Mulay. 2020. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19. *Cells* 9(6):1383.
- 54) Sahebnaasagh, A., F. Saghafi, M. Safdari, M. Khataminia, A. Sadremomtaz, Z. Talaei 6, H. R. Ghaleno, M. Bagheri, S. Habtemariam, and R. Avan. 2020. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. *J Clin Pharm Ther* 45:1515-1519.
- 55) Parackova, Z., M. Bloomfield, A. Klocperk, and A. Sediva. 2021. Neutrophils mediate Th17 promotion in COVID-19 patients. *J Leukoc Biol* 109:73-76.
- 56) Pacha, O., M. A. Sallman, and S. E. Evans. 2020. COVID-19: a case for inhibiting IL-17? . *Nat Rev Immunol* 20:345-346.
- 57) Barnes, B. J, J. M. Adrover, A. Baxter-Stoltzfus, Al. Borczuk, J. Cools-Lartigue, J. M.

- Crawford, J. Daßler-Plenker, P. Guerci, C. Huyn, J. S. Knight, M. Loda, M. R. Looney, F. McAllister, R. Rayes, S. Renaud, S. Rousseau, S. Salvatore, R. E. Schwartz, J. D. Spicer, C. C. Yost, A. Weber, Y. Zuo, and M. Egeblad. 2020. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *J Exp Med* 217:e20200652.
- 58) Xu, Z., L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, S. Liu, P. Zhao, H. Liu 1, L. Zhu, Y. Tai, C. Bai, T. Gao, J. Song, P. Xia, J. Dong, J. Zhao, and F. Wang . 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 8:420-422
- 59) Uyemura, K., M. Yamamura, D. F. Fivenson, R. L. Modlin, and B. J. Nickoloff. 1993. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. *J. Invest. Dermatol.* 101: 701-705.
- 60) Brembilla, N. C., L. Senra, and W. Boehncke. 2018. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. *Front Immunol* 9:1682.
- 61) Tang, C., S. Chen, H. Qian, W. Huang. 2012. Interleukin-23: as a drug target for autoimmune inflammatory diseases. *Immunology* 135:112-124.
- 62) Boutet MA, A. Nerviani, G. G. Affitto, and C. Pitzalis. 2018. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. *Int J Mol Sci* 19:530.
- 63) Lai, Y., D. Li, C. Li, B. Muehleisen, K. A. Radek, H. J. Park, Z. Jiang, Z. Li, H. Lei, Y. Quan, T. Zhang, Y. Wu, P. Kotol, S. Morizane, T. R Hata, K. Iwatsuki, C Tang, and R. L. Gallo. 2012. The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. *Immunity* 37:74-84.
- 64) Alchera, E., S. Rolla, C. Imarisio, V. Bardina, G. Valente, F. Novelli, and R. Carini. 2017. Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity. *Transl Res* 182:

75-87.

- 65) Wang, L., H. Wan, W. Tang, Y. Ni, X. Hou, L. Pan, Y. Song, and G. Shi. 2018. Critical roles of adenosine A2A receptor in regulating the balance of Treg/Th17 cells in allergic asthma. *Clin Respir J* 12: 149-157.
- 66) Ansari, M. A., A. Nadeem, S. M. Attia, S. A. Bakheet, M. Raish, and S. F. Ahmad. 2017. Adenosine A2A receptor modulates neuroimmune function through Th17/retinoid-related orphan receptor gamma t (RORgammat) signaling in a BTBR T(+) Itpr3(tf)/J mouse model of autism. *Cell Signal* 36: 14-24.
- 67) Latini, S., and F. Pedata. 2001. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. *J Neurochem* 79:463-84
- 68) Engler, R.L. 1991. Adenosine. The signal of life?. *Circulation* 84: 951-954

Figure legends

Figure 1.

An adenosine A2a receptor antagonist, istradefylline, suppresses OVA-induced neutrophilic airway inflammation in DO11.10 mice. (A) The protocol of the OVA-induced neutrophilic airway inflammation assay. (B, C) Lung homogenate was assayed for concentrations of IL-17A by an ELISA (n=7-10). (D) Lung homogenate was assayed for concentrations of IL-17A (left), IFN- γ (center), or IL-5 (right) by an ELISA (n=7-10). Data are expressed as the mean $\pm$ SD and were compared using an unpaired Student's *t*-test. **P* < 0.05 and ***P* < 0.01, in comparison to the value of water (challenged OVA).

Figure 2.

Histological findings. Istradefylline suppresses OVA-induced neutrophil and infiltration in DO11.10 mice. Lungs sections from mice administered oral water (A) or istradefylline (B)

were stained with hematoxylin and eosin (Scale bar, 50 μ m).

Figure 3.

Inhibitor of CD39 (ARL67156) and inhibitor of CD73 (AMP-CP) suppresses OVA-induced neutrophilic airway inflammation in DO11.10 mice. DO11.10 mice were treated as described for Fig.1. Lung homogenate was assayed for concentrations of IL-17A by an ELISA (n=7-10). Data are expressed as the mean $\pm$ SD and were compared using an unpaired Student's *t*-test. *P < 0.05 and **P < 0.01 in comparison to the value of water (challenged OVA).

Figure 4.

Istradefylline, ARL67156, and AMP-CP suppress IMQ-induced psoriasis in mice. Mice were treated with either IMQ cream containing 5% IMQ or sham cream and the ear thickness (μ m) was measured. In treatment groups, cream containing 5% istradefylline, liquid containing 10 mM ARL67156, or liquid containing 10 mM AMP-CP inhibitor was used. Data were obtained from three independent experiments (n = 3-4 mice/group). Data are expressed as the mean $\pm$ SD and were compared using an unpaired Student's *t*-test. *P < 0.05 and **P < 0.01, in comparison to the value of the non-treatment group.

Fig1

A

B

C

D

Fig2

A

Water

B

Istradefylline

Fig3

A

B

Fig4

A

B

C